CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine

M Lopes-Pacheco - Frontiers in pharmacology, 2020 - frontiersin.org
Cystic fibrosis (CF) is a lethal inherited disease caused by mutations in the CF
transmembrane conductance regulator (CFTR) gene, which result in impairment of CFTR …

Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications

MA Mall, N Mayer-Hamblett… - American journal of …, 2020 - atsjournals.org
Cystic fibrosis (CF) remains the most common life-shortening hereditary disease in white
populations, with high morbidity and mortality related to chronic airway mucus obstruction …

A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion

J Sharma, M Du, E Wong, V Mutyam, Y Li… - Nature …, 2021 - nature.com
Premature termination codons (PTCs) prevent translation of a full-length protein and trigger
nonsense-mediated mRNA decay (NMD). Nonsense suppression (also termed readthrough) …

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

FJ Accurso, SM Rowe, JP Clancy… - … England Journal of …, 2010 - Mass Medical Soc
Background A new approach in the treatment of cystic fibrosis involves improving the
function of mutant cystic fibrosis transmembrane conductance regulator (CFTR). VX-770, a …

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

JP Clancy, SM Rowe, FJ Accurso, ML Aitken, RS Amin… - Thorax, 2012 - thorax.bmj.com
Background VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR)
modulator, has been shown to increase the cell surface density of functional F508del-CFTR …

Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine

I Pranke, A Golec, A Hinzpeter, A Edelman… - Frontiers in …, 2019 - frontiersin.org
An improved understanding of the cystic fibrosis (CF) transmembrane conductance regulator
(CFTR) protein structure and the consequences of CFTR gene mutations have allowed the …

New and emerging targeted therapies for cystic fibrosis

BS Quon, SM Rowe - Bmj, 2016 - bmj.com
Cystic fibrosis (CF) is a monogenic autosomal recessive disorder that affects about 70 000
people worldwide. The clinical manifestations of the disease are caused by defects in the …

Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons

M Dabrowski, Z Bukowy-Bieryllo, E Zietkiewicz - Molecular medicine, 2018 - Springer
Premature termination codons (PTCs) in the coding regions of mRNA lead to the incorrect
termination of translation and generation of non-functional, truncated proteins. Translational …

Sense from nonsense: therapies for premature stop codon diseases

L Bidou, V Allamand, JP Rousset, O Namy - Trends in molecular medicine, 2012 - cell.com
Ten percent of inherited diseases are caused by premature termination codon (PTC)
mutations that lead to degradation of the mRNA template and to the production of a non …

Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis

I Sermet-Gaudelus, KD Boeck, GJ Casimir… - American journal of …, 2010 - atsjournals.org
Rationale: Nonsense (premature stop codon) mutations in mRNA for the cystic fibrosis
transmembrane conductance regulator (CFTR) cause cystic fibrosis (CF) in approximately …